关注
Matthijs Versteegh, PhD
Matthijs Versteegh, PhD
Institute for Medical Technology Assessment
在 imta.eur.nl 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Dutch tariff for the five-level version of EQ-5D
MM Versteegh, KM Vermeulen, SMAA Evers, GA De Wit, R Prenger, ...
Value in health 19 (4), 343-352, 2016
6712016
Time trade-off: one methodology, different methods
AE Attema, Y Edelaar-Peeters, MM Versteegh, EA Stolk
The European Journal of Health Economics 14, 53-64, 2013
1372013
Patient and general public preferences for health states: a call to reconsider current guidelines
MM Versteegh, WBF Brouwer
Social Science & Medicine 165, 66-74, 2016
1242016
Introducing the composite time trade-off: a test of feasibility and face validity
BMF Janssen, M Oppe, MM Versteegh, EA Stolk
The European Journal of Health Economics 14, 5-13, 2013
1202013
Condition-specific preference-based measures: benefit or burden?
MM Versteegh, A Leunis, CA Uyl-de Groot, EA Stolk
Value in Health 15 (3), 504-513, 2012
1072012
When is it too expensive? Cost-effectiveness thresholds and health care decision-making
W Brouwer, P van Baal, J van Exel, M Versteegh
The European Journal of Health Economics 20, 175-180, 2019
872019
From good to better: new Dutch guidelines for economic evaluations in healthcare
M Versteegh, S Knies, W Brouwer
Pharmacoeconomics 34, 1071-1074, 2016
812016
Mapping onto Eq-5 D for patients in poor health
MM Versteegh, D Rowen, JE Brazier, EA Stolk
Health and Quality of life Outcomes 8, 1-13, 2010
722010
Mapping Qlq-C30, Haq, and Msis-29 on Eq-5d
MM Versteegh, A Leunis, JJ Luime, M Boggild, CA Uyl-de Groot, EA Stolk
Medical Decision Making 32 (4), 554-568, 2012
602012
Severity-adjusted probability of being cost effective
MM Versteegh, IC Ramos, NC Buyukkaramikli, A Ansaripour, ...
Pharmacoeconomics 37, 1155-1163, 2019
582019
Lead time TTO: leading to better health state valuations?
AE Attema, MM Versteegh, M Oppe, WBF Brouwer, EA Stolk
Health economics 22 (4), 376-392, 2013
482013
Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
S de Groot, WK Redekop, MM Versteegh, S Sleijfer, E Oosterwijk, ...
Quality of Life Research 27, 115-124, 2018
452018
A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending
P van Baal, M Perry‐Duxbury, P Bakx, M Versteegh, E Van Doorslaer, ...
Health economics 28 (1), 87-100, 2019
432019
Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the …
IC Ramos, MM Versteegh, RA de Boer, JMA Koenders, GCM Linssen, ...
Value in Health 20 (10), 1260-1269, 2017
382017
Are health state valuations from the general public biased? A test of health state reference dependency using self‐assessed health and an efficient discrete choice experiment
MF Jonker, AE Attema, B Donkers, EA Stolk, MM Versteegh
Health economics 26 (12), 1534-1547, 2017
332017
An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences
R Crott, M Versteegh, C Uyl-de-Groot
Quality of Life Research 22, 1045-1054, 2013
332013
Psychometric evaluation of the Dutch translation of the Overall Assessment of the Speaker's Experience of Stuttering for adults (OASES-AD)
C Koedoot, M Versteegh, JS Yaruss
Journal of Fluency Disorders 36 (3), 222-230, 2011
302011
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
MM Versteegh, AE Attema, M Oppe, NJ Devlin, EA Stolk
The European Journal of Health Economics 14, 43-51, 2013
282013
Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options
MF Jonker, B Donkers, LMA Goossens, RJ Hoefman, LJ Jabbarian, ...
Medical Decision Making 40 (2), 198-211, 2020
242020
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
DT Arnold, D Rowen, MM Versteegh, A Morley, CE Hooper, NA Maskell
Health and quality of life outcomes 13, 1-10, 2015
212015
系统目前无法执行此操作,请稍后再试。
文章 1–20